Esperion Therapeutics (NASDAQ:ESPR) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.36, Bloomberg Earnings reports. During the same period in the previous year, the business posted ($1.29) EPS.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at $74.92 on Tuesday. The company has a market cap of $1,962.73, a PE ratio of -10.91 and a beta of 2.64. Esperion Therapeutics has a 12-month low of $20.39 and a 12-month high of $82.18.
In related news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 32.50% of the stock is owned by company insiders.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.